Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 3:2019:7495629.
doi: 10.1155/2019/7495629. eCollection 2019.

The Signaling of Cellular Senescence in Diabetic Nephropathy

Affiliations
Review

The Signaling of Cellular Senescence in Diabetic Nephropathy

Yabing Xiong et al. Oxid Med Cell Longev. .

Abstract

Diabetic nephropathy is the leading cause of chronic kidney disease (CKD) in western countries. Notably, it has a rapidly rising prevalence in China. The patients, commonly complicated with cardiovascular diseases and neurologic disorders, are at high risk to progress into end-stage renal disease (ESRD) and death. However, the pathogenic mechanisms of diabetic nephropathy have not been determined. Cellular senescence, which recently has gained broad attention, is thought to be an important player in the onset and development of diabetic nephropathy. In this issue, we generally review the mechanisms of cellular senescence in diabetic nephropathy, which involve telomere attrition, DNA damage, epigenetic alterations, mitochondrial dysfunction, loss of Klotho, Wnt/β-catenin signaling activation, persistent inflammation, and accumulation of uremic toxins. Moreover, we highlight the potential therapeutic targets of cellular senescence in diabetic nephropathy and provide important clues for clinical strategies.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests in this paper.

Figures

Figure 1
Figure 1
The cellular senescence in diabetic nephropathy.
Figure 2
Figure 2
Therapeutic potentials against cellular senescence in diabetic nephropathy.

References

    1. Bell S., Fletcher E. H., Brady I., et al. End-stage renal disease and survival in people with diabetes: a national database linkage study. QJM. 2015;108(2):127–134. doi: 10.1093/qjmed/hcu170. - DOI - PMC - PubMed
    1. Kato M., Natarajan R. Diabetic nephropathy—emerging epigenetic mechanisms. Nature Reviews Nephrology. 2014;10(9):517–530. doi: 10.1038/nrneph.2014.116. - DOI - PMC - PubMed
    1. World Health Organization. Diabetes—Fact Sheet No. 312. Geneva: World Health Organization; 2015.
    1. Heerspink H. J. L., Parving H. H., Andress D. L., et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937–1947. doi: 10.1016/S0140-6736(19)30772-X. - DOI - PubMed
    1. Rao Kondapally Seshasai S., Kaptoge S., Thompson A., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. New England Journal of Medicine. 2011;364(9):829–841. doi: 10.1056/nejmoa1008862. - DOI - PMC - PubMed